A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
This is a Phase 2 study to assess the efficacy of SB1518 in the treatment of patients with advanced lymphoid malignancies including Hodgkin Lymphoma, Mantle Cell Lymphoma and Indolent Lymphoma (follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma and small lymphocytic lymphoma).
Hodgkin Lymphoma|Mantle Cell Lymphoma|Indolent Lymphoma
DRUG: SB1518
Assess overall tumor response of SB1518 by CT/FDG-PET scan and bone marrow biopsy as applicable as a measure of efficacy, Outcome Measure - To assess the efficacy of SB1518 in the treatment of patients with advanced lymphoid malignancies including Hodgkin Lymphoma, Mantle Cell Lymphoma and Indolent Lymphoma (follicular lymphoma, lymphophasmacytic lymphoma, marginal zone lymphoma and small lymphocytic lymphoma)., Every even numbered cycle from baseline to 30 days after the last dose of study medication
Assess durability of response, To assess the durability of response following SB1518 treatment in patients with advanced lymphoid malignancies., Every even numbered cycle from baseline to 30 days after the last dose of study medication|Assess number of patients with adverse events as a measure of safety and tolerability, To assess the safety and tolerability of SB1518 administered orally once daily in patients with advanced lymphoid malignancies., Every even numbered cycle from baseline to 30 days after the last dose of study medication
This is a Phase 2 study to assess the efficacy of SB1518 in the treatment of patients with advanced lymphoid malignancies including Hodgkin Lymphoma, Mantle Cell Lymphoma and Indolent Lymphoma (follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma and small lymphocytic lymphoma).